
Guillermo Torre-Amione

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2370606/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Long term development of diastolic dysfunction and heart failure with preserved left ventricular ejection fraction in heart transplant recipients. Scientific Reports, 2022, 12, 3834.	3.3	2
2	A Case Series of Reversible Acute Cardiomyopathy Associated with H1N1 Influenza Infection. Methodist DeBakey Cardiovascular Journal, 2021, 8, 42.	1.0	10
3	The Role of B-Cells in Heart Failure. Methodist DeBakey Cardiovascular Journal, 2021, 9, 15.	1.0	25
4	Heart Failure: An Illness at the Juncture of Molecular Medicine and New Technology. Methodist DeBakey Cardiovascular Journal, 2021, 9, 2.	1.0	0
5	Use of Stem Cells in Heart Failure Treatment: Where We Stand and Where We Are Going. Methodist DeBakey Cardiovascular Journal, 2021, 9, 195.	1.0	12
6	Pulse assessment is important with blood pressure measurement in individuals with continuous flow left ventricular assist devices. International Journal of Artificial Organs, 2021, 44, 124-129.	1.4	2
7	Heat shock protein 60 and cardiovascular diseases: An intricate loveâ€hate story. Medicinal Research Reviews, 2021, 41, 29-71.	10.5	25
8	Outbreak of Candida auris infection in a COVID-19 hospital in Mexico. Clinical Microbiology and Infection, 2021, 27, 813-816.	6.0	122
9	Remote versus early corticosteroid wean outcomes in heart transplant recipients in the contemporary era. Clinical Transplantation, 2021, 35, e14382.	1.6	0
10	Endothelial Dysfunction-related Neurological Bleeds with Continuous Flow-Left Ventricular Assist Devices Measured by Digital Thermal Monitor. ASAIO Journal, 2021, 67, 561-566.	1.6	1
11	Abstract 11435: A New Paradigm in Therapy: A Vaccine Against the Progression of Heart Failure. Circulation, 2021, 144, .	1.6	0
12	What Is the Role of the Inflammation in the Pathogenesis of Heart Failure?. Current Cardiology Reports, 2020, 22, 139.	2.9	36
13	The role of B cells in heart failure and implications for future immunomodulatory treatment strategies. ESC Heart Failure, 2020, 7, 1387-1399.	3.1	33
14	Resveratrol Prevents Right Ventricle Remodeling and Dysfunction in Monocrotaline-Induced Pulmonary Arterial Hypertension with a Limited Improvement in the Lung Vasculature. Oxidative Medicine and Cellular Longevity, 2020, 2020, 1-13.	4.0	21
15	Role of Endothelial and Mesenchymal Cell Transitions in Heart Failure and Recovery Thereafter. Frontiers in Genetics, 2020, 11, 609262.	2.3	5
16	Percutaneous Left Axillary Artery Placement of Intra-Aortic Balloon Pump in Advanced HeartÂFailure Patients. JACC: Heart Failure, 2020, 8, 313-323.	4.1	52
17	Management of Myocarditis-Related Cardiomyopathy in Adults. Circulation Research, 2019, 124, 1568-1583.	4.5	179
18	Phase II clinical trial testing the safety of a humanised monoclonal antibody anti-CD20 in patients with heart failure with reduced ejection fraction, ICFEr-RITU2: study protocol. BMJ Open, 2019, 9, e022826.	1.9	14

#	Article	IF	CITATIONS
19	Mitochondrial Hyperacetylation in the Failing Hearts of Obese Patients Mediated Partly by a Reduction in SIRT3: The Involvement of the Mitochondrial Permeability Transition Pore. Cellular Physiology and Biochemistry, 2019, 53, 465-479.	1.6	46
20	Incidence and outcomes of cancer treatment-related cardiomyopathy among referrals for advanced heart failure. Cardio-Oncology, 2018, 4, 3.	1.7	9
21	Systolic blood pressure reduction during the first 24 h in acute heart failure admission: friend or foe?. European Journal of Heart Failure, 2018, 20, 317-322.	7.1	20
22	Risk Stratification of Patients With Current Generation Continuous-Flow Left Ventricular Assist Devices Being Bridged to Heart Transplantation. ASAIO Journal, 2018, 64, 196-202.	1.6	7
23	Temporal Frame of Immune Cell Infiltration during Heart Failure Establishment: Lessons from Animal Models. International Journal of Molecular Sciences, 2018, 19, 3719.	4.1	15
24	B-type natriuretic peptide reference interval of newborns from healthy and pre-eclamptic women: a prospective, multicentre, cross-sectional study. BMJ Open, 2018, 8, e022562.	1.9	8
25	The Cardioprotective Effect of Breg Cells Induced by Methotrexate. FASEB Journal, 2018, 32, 718.6.	0.5	Ο
26	The use of cardiac CT as a roadmap for resolving coronary stent dislodgement. Archivos De Cardiologia De Mexico, 2018, 88, 318-319.	0.2	1
27	Measurement of troponin and natriuretic peptides shortly after admission in patients with heart failure—does it add useful prognostic information? An analysis of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Studies (<scp>VERITAS</scp>). European Journal of Heart Failure, 2017, 19, 739-747.	7.1	28
28	Myocardial Recovery in Patients With Systolic Heart Failure and Autoantibodies Against β 1 -Adrenergic Receptors. Journal of the American College of Cardiology, 2017, 69, 968-977.	2.8	28
29	Prevalence of inâ€hospital nonsteroidal antiinflammatory drug exposure in patients with a primary diagnosis of heart failure. Cardiovascular Therapeutics, 2017, 35, e12256.	2.5	4
30	Melding a High-Risk Patient for Continuous Flow Left Ventricular Assist Device into a Low-Risk Patient. ASAIO Journal, 2017, 63, 704-712.	1.6	8
31	Role of Adaptive Immunity in the Development and Progression of Heart Failure: New Evidence. Archives of Medical Research, 2017, 48, 1-11.	3.3	34
32	Rapamycin nanoparticles localize in diseased lung vasculature and prevent pulmonary arterial hypertension. International Journal of Pharmaceutics, 2017, 524, 257-267.	5.2	31
33	Silica nanoparticles induce cardiotoxicity interfering with energetic status and Ca ²⁺ handling in adult rat cardiomyocytes. American Journal of Physiology - Heart and Circulatory Physiology, 2017, 312, H645-H661.	3.2	49
34	Small Interfering RNA Targeting Mitochondrial Calcium Uniporter Improves Cardiomyocyte Cell Viability in Hypoxia/Reoxygenation Injury by Reducing Calcium Overload. Oxidative Medicine and Cellular Longevity, 2017, 2017, 1-13.	4.0	31
35	A specifically designed nanoconstruct associates, internalizes, traffics in cardiovascular cells, and accumulates in failing myocardium: a new strategy for heart failure diagnostics and therapeutics. European Journal of Heart Failure, 2016, 18, 169-178.	7.1	31
36	Acquired and Hereditary Hypercoagulable States in Patients with Continuous Flow Left Ventricular Assist Devices: Prevalence and Thrombotic Complications. Journal of Cardiac Failure, 2016, 22, 501-511.	1.7	13

#	Article	IF	CITATIONS
37	Rnd3/RhoE Modulates Hypoxia-Inducible Factor 1α/Vascular Endothelial Growth Factor Signaling by Stabilizing Hypoxia-Inducible Factor 1α and Regulates Responsive Cardiac Angiogenesis. Hypertension, 2016, 67, 597-605.	2.7	40
38	Full Expression of Cardiomyopathy Is Partly Dependent on B ells: AÂPathway That Involves Cytokine Activation, Immunoglobulin Deposition, and Activation of Apoptosis. Journal of the American Heart Association, 2016, 5, .	3.7	67
39	Combination of angiotensin II and l-NG-nitroarginine methyl ester exacerbates mitochondrial dysfunction and oxidative stress to cause heart failure. American Journal of Physiology - Heart and Circulatory Physiology, 2016, 310, H667-H680.	3.2	22
40	Predictors and Associations With Outcomes of Length of Hospital Stay in Patients With Acute Heart Failure: Results From VERITAS. Journal of Cardiac Failure, 2016, 22, 815-822.	1.7	27
41	Differential Mitochondrial Function in Remodeled Right and Nonremodeled Left Ventricles in Pulmonary Hypertension. Journal of Cardiac Failure, 2016, 22, 73-81.	1.7	8
42	Impact of pre-operative coronary artery disease on cardiovascular events following lung transplantation. Journal of Heart and Lung Transplantation, 2016, 35, 115-121.	0.6	26
43	Acute Heart Failure in the Elderly: Differences in Clinical Characteristics, Outcomes, and Prognostic Factors in the VERITAS Study. Journal of Cardiac Failure, 2015, 21, 179-188.	1.7	65
44	Persistent Blood Stream Infection in Patients Supported With a Continuous-Flow Left Ventricular Assist Device Is Associated With an Increased Risk of Cerebrovascular Accidents. Journal of Cardiac Failure, 2015, 21, 119-125.	1.7	85
45	Impaired oxidative metabolism and calcium mishandling underlie cardiac dysfunction in a rat model of post-acute isoproterenol-induced cardiomyopathy. American Journal of Physiology - Heart and Circulatory Physiology, 2015, 308, H467-H477.	3.2	60
46	Standardized extracts from black bean coats (Phaseolus vulgaris L.) prevent adverse cardiac remodeling in a murine model of non-ischemic cardiomyopathy. RSC Advances, 2015, 5, 90858-90865.	3.6	6
47	Isolation and chemical identification of lipid derivatives from avocado (Persea americana) pulp with antiplatelet and antithrombotic activities. Food and Function, 2015, 6, 192-202.	4.6	35
48	Worsening heart failure, a critical event during hospital admission for acute heart failure: results from the <scp>VERITAS</scp> study. European Journal of Heart Failure, 2014, 16, 1362-1371.	7.1	28
49	Spinal cord stimulation is safe and feasible in patients with advanced heart failure: early clinical experience. European Journal of Heart Failure, 2014, 16, 788-795.	7.1	30
50	High proportion of patients with end-stage heart failure regardless of aetiology demonstrates anti-cardiac antibody deposition in failing myocardium: humoral activation, a potential contributor of disease progression. European Heart Journal, 2014, 35, 1061-1068.	2.2	41
51	A simplified echocardiographic technique for detecting continuous-flow left ventricular assist device malfunction due to pump thrombosis. Journal of Heart and Lung Transplantation, 2014, 33, 575-586.	0.6	38
52	Freshly isolated mitochondria from failing human hearts exhibit preserved respiratory function. Journal of Molecular and Cellular Cardiology, 2014, 68, 98-105.	1.9	49
53	Molecular and Cellular Correlates of Cardiac Function in End-Stage DCM. JACC: Cardiovascular Imaging, 2014, 7, 441-452.	5.3	32
54	Mechanical Unloading Promotes Myocardial Energy Recovery in Human Heart Failure. Circulation: Cardiovascular Genetics, 2014, 7, 266-276.	5.1	76

#	Article	IF	CITATIONS
55	Echocardiographic Evaluation of Hemodynamics in Patients With Systolic Heart Failure Supported by a Continuous-Flow LVAD. Journal of the American College of Cardiology, 2014, 64, 1231-1241.	2.8	63
56	Atrial arrhythmias after lung transplant: Underlying mechanisms, risk factors, and prognosis. Journal of Heart and Lung Transplantation, 2014, 33, 734-740.	0.6	49
57	Effects of Spironolactone Treatment in Elderly Women With Heart Failure and Preserved Left Ventricular Ejection Fraction. Journal of Cardiac Failure, 2014, 20, 560-568.	1.7	38
58	Increased right-to-left ventricle diameter ratio is a strong predictor of right ventricular failure after left ventricular assist device. Journal of Heart and Lung Transplantation, 2013, 32, 792-799.	0.6	98
59	Percutaneous Placement of an Intra-Aortic Balloon Pump in the Left Axillary/Subclavian Position Provides Safe, Ambulatory Long-Term Support as Bridge to Heart Transplantation. JACC: Heart Failure, 2013, 1, 382-388.	4.1	135
60	Comparison of Transendocardial and Intracoronary CD34 ⁺ Cell Transplantation in Patients With Nonischemic Dilated Cardiomyopathy. Circulation, 2013, 128, S42-9.	1.6	169
61	Effects of Intracoronary CD34 ⁺ Stem Cell Transplantation in Nonischemic Dilated Cardiomyopathy Patients. Circulation Research, 2013, 112, 165-173.	4.5	256
62	The physiology of cardiovascular disease and innovative liposomal platforms for therapy. International Journal of Nanomedicine, 2013, 8, 629.	6.7	24
63	Molecular, Cellular, and Functional Characterization of Myocardial Regions in Hypertrophic Cardiomyopathy. Circulation: Cardiovascular Imaging, 2012, 5, 419-422.	2.6	8
64	Imaging for Ventricular Function and Myocardial Recovery on Nonpulsatile Ventricular Assist Devices. Circulation, 2012, 125, 2265-2277.	1.6	33
65	Allograft Coronary Artery Thrombosis: A Case Report Of Early Cardiac Allograft Left Ventricular Myocardial Infarction. Methodist DeBakey Cardiovascular Journal, 2012, 8, 46-48.	1.0	2
66	Relationship of right- and left-sided filling pressures in patients with advanced heart failure: A 14-year multi-institutional analysis. Journal of Heart and Lung Transplantation, 2012, 31, 67-72.	0.6	52
67	Myocardial Recovery in Peripartum Cardiomyopathy: Prospective Comparison With Recent Onset Cardiomyopathy in Men and Nonperipartum Women. Journal of Cardiac Failure, 2012, 18, 28-33.	1.7	91
68	Left Ventricular Assist Device Support and Myocardial Recovery in Recent Onset Cardiomyopathy. Journal of Cardiac Failure, 2012, 18, 755-761.	1.7	61
69	Usefulness of routine surveillance endomyocardial biopsy 6 months after heart transplantation. Journal of Heart and Lung Transplantation, 2012, 31, 845-849.	0.6	33
70	Cellular, Molecular, Genomic, and Functional Changes That Occur in the Failing Heart in Response to Mechanical Circulatory Support. , 2012, , 258-271.		2
71	Effects of Intracoronary Stem Cell Transplantation in Patients With Dilated Cardiomyopathy. Journal of Cardiac Failure, 2011, 17, 272-281.	1.7	93
72	Initial Clinical Experience Of Total Cardiac Replacement With Dual Heartmate-II [®] Axial Flow Pumps For Severe Biventricular Heart Failure. Methodist DeBakey Cardiovascular Journal, 2011, 7, 40-44.	1.0	33

#	Article	IF	CITATIONS
73	Cellular Evidence of Reverse Cardiac Remodeling Induced by Cardiac Resynchronization Therapy. Congestive Heart Failure, 2011, 17, 140-146.	2.0	22
74	Immune Modulation in Heart Failure: Past Challenges and Future Hopes. Current Heart Failure Reports, 2011, 8, 28-37.	3.3	25
75	Therapeutic plasma exchange a potential strategy for patients with advanced heart failure. Journal of Clinical Apheresis, 2010, 25, 323-330.	1.3	21
76	Reversal of secondary pulmonary hypertension by axial and pulsatile mechanical circulatory support. Journal of Heart and Lung Transplantation, 2010, 29, 195-200.	0.6	76
77	Abnormal Mitochondrial Function During Ischemia Reperfusion Provides Targets For Pharmacological Therapy. Methodist DeBakey Cardiovascular Journal, 2009, 5, 2-7.	1.0	20
78	Left Atrial Function in Diastolic Heart Failure. Circulation: Cardiovascular Imaging, 2009, 2, 10-15.	2.6	385
79	Reciprocal Regulation of Myocardial microRNAs and Messenger RNA in Human Cardiomyopathy and Reversal of the microRNA Signature by Biomechanical Support. Circulation, 2009, 119, 1263-1271.	1.6	292
80	Early Worsening Heart Failure in Patients Admitted for Acute Heart Failure: Time Course, Hemodynamic Predictors, and Outcome. Journal of Cardiac Failure, 2009, 15, 639-644.	1.7	56
81	The Role of Multimodality Cardiac Imaging in the Transplanted Heart. JACC: Cardiovascular Imaging, 2009, 2, 1126-1140.	5.3	50
82	Assessment of Left Ventricular Relaxation by Untwisting Rate Based on Different Algorithms. Journal of the American Society of Echocardiography, 2009, 22, 1040-1046.	2.8	9
83	Heart Failure In Search Of A Cure. Methodist DeBakey Cardiovascular Journal, 2009, 5, 1-1.	1.0	0
84	Heart Failure Research: Translating Basic Science Into Therapies. Methodist DeBakey Cardiovascular Journal, 2009, 5, 38-41.	1.0	0
85	Effect of the Soluble TNFâ€Antagonist Etanercept on Tumor Necrosis Factor Bioactivity and Stability. Clinical and Translational Science, 2008, 1, 142-145.	3.1	22
86	Off-pump Exchange of Short-term Percutaneous Ventricular Assist Device (VAD) to Long-term Implantable VAD in Severe Coagulopathy and Multi-organ Failure. Journal of Heart and Lung Transplantation, 2008, 27, 572-574.	0.6	6
87	Increased Expression of Stem Cell Factor and Its Receptor After Left Ventricular Assist Device Support: A Potential Novel Target for Therapeutic Interventions in Heart Failure. Journal of Heart and Lung Transplantation, 2008, 27, 701-709.	0.6	16
88	The Use of Continuous Milrinone Therapy as Bridge to Transplant Is Safe in Patients With Short Waiting Times. Journal of Cardiac Failure, 2008, 14, 839-843.	1.7	27
89	Results of a non-specific immunomodulation therapy in chronic heart failure (ACCLAIM trial): a placebo-controlled randomised trial. Lancet, The, 2008, 371, 228-236.	13.7	159
90	Non-specific immunomodulation in chronic heart failure – Author's reply. Lancet, The, 2008, 371, 2084.	13.7	0

#	Article	IF	CITATIONS
91	Response to Letter Regarding Article, "Left Ventricular Untwisting Rate by Speckle Tracking Echocardiography― Circulation, 2008, 117, .	1.6	0
92	The Role of Mast Cells After Solid Organ Transplantation. Transplantation, 2008, 85, 1365-1371.	1.0	16
93	Evidence for activation of immune system in heart failure: is there a role for anti-inflammatory therapy?. Current Opinion in Cardiology, 2008, 23, 254-260.	1.8	34
94	Cytokines and acute heart failure. Critical Care Medicine, 2008, 36, S9-S16.	0.9	98
95	Global Diastolic Strain Rate for the Assessment of Left Ventricular Relaxation and Filling Pressures. Circulation, 2007, 115, 1376-1383.	1.6	339
96	Effects of Tezosentan on Symptoms and Clinical Outcomes in Patients With Acute Heart Failure. JAMA - Journal of the American Medical Association, 2007, 298, 2009.	7.4	330
97	Left Ventricular Untwisting Rate by Speckle Tracking Echocardiography. Circulation, 2007, 116, 2580-2586.	1.6	164
98	Cardiac Improvement During Mechanical Circulatory Support. Circulation, 2007, 115, 2497-2505.	1.6	376
99	Response to Letter by Weidemann et al Regarding Article, "Global Diastolic Strain Rate for the Assessment of Left Ventricular Relaxation and Filling Pressure― Circulation, 2007, 116, .	1.6	1
100	The Effect of Etanercept on Cardiac Transplant Recipients: A Study of TNFα Antagonism and Cardiac Allograft Hypertrophy. Transplantation, 2007, 84, 480-483.	1.0	14
101	Mast Cell-Derived Cathepsin g: A Possible Role in The Adverse Remodeling of The Failing Human Heart. Journal of Surgical Research, 2007, 140, 199-203.	1.6	24
102	Decorin-mediated Transforming Growth Factor-β Inhibition Ameliorates Adverse Cardiac Remodeling. Journal of Heart and Lung Transplantation, 2007, 26, 34-40.	0.6	51
103	Recurrent Device Thrombi During Mechanical Circulatory Support With an Axial-flow Pump Is a Treatable Condition and Does Not Preclude Successful Long-term Support. Journal of Heart and Lung Transplantation, 2007, 26, 200-203.	0.6	18
104	Long-term Outcomes of Cardiac Transplantation for Peri-partum Cardiomyopathy: A Multiinstitutional Analysis. Journal of Heart and Lung Transplantation, 2007, 26, 1097-1104.	0.6	47
105	A study to assess the effects of a broad-spectrum immune modulatory therapy on mortality and morbidity in patients with chronic heart failure: The ACCLAIM trial rationale and design. Canadian Journal of Cardiology, 2007, 23, 369-376.	1.7	13
106	Preserved left ventricular twist and circumferential deformation, but depressed longitudinal and radial deformation in patients with diastolic heart failure. European Heart Journal, 2007, 29, 1283-1289.	2.2	354
107	Systolic and Diastolic Dyssynchrony in Patients With Diastolic Heart Failure and the Effect of Medical Therapy. Journal of the American College of Cardiology, 2007, 49, 88-96.	2.8	163
108	A Phase 1–2 Dose-Escalating Study Evaluating the Safety and Tolerability of Istaroxime and Specific Effects on Electrocardiographic and Hemodynamic Parameters in Patients with Chronic Heart Failure with Reduced Systolic Function. American Journal of Cardiology, 2007, 99, S47-S56.	1.6	41

2.8

53

#	Article	IF	CITATIONS
109	Heart Rhythm Considerations in Heart Transplant Candidates and Considerations for Ventricular Assist Devices: International Society for Heart and Lung Transplantation Guidelines for the Care of Cardiac Transplant Candidates—2006. Journal of Heart and Lung Transplantation, 2006, 25, 1043-1056.	0.6	70
110	Chronic Heart Failure: A Report From the Dartmouth Diastole Discourses. Congestive Heart Failure, 2006, 12, 162-165.	2.0	21
111	Dynamic Expression of the Membrane Attack Complex (MAC) of the Complement System in Failing Human Myocardium. American Journal of Cardiology, 2006, 97, 1626-1629.	1.6	18
112	Novel therapies for heart failure: focus on anti-inflammatory strategies. Congestive Heart Failure, 2006, 12, 153-9; quiz 160-1.	2.0	6
113	Statin use and risks of death or fatal rejection in the Heart Transplant Lipid Registry. American Journal of Cardiology, 2005, 95, 367-372.	1.6	43
114	Immune Activation in Chronic Heart Failure. American Journal of Cardiology, 2005, 95, 3-8.	1.6	230
115	Broad Modulation of Tissue Responses (Immune Activation) by Celacade May Favorably Influence Pathologic Processes Associated with Heart Failure Progression. American Journal of Cardiology, 2005, 95, 30-37.	1.6	16
116	Echocardiographic ejection fraction in patients with acute heart failure: correlations with hemodynamic, clinical, and neurohormonal measures and short-term outcome. European Journal of Heart Failure, 2005, 7, 815-819.	7.1	19
117	Simvastatin decreases myocardial tumor necrosis factor α content in heart transplant recipients. Journal of Heart and Lung Transplantation, 2005, 24, 46-51.	0.6	32
118	Placement of a left ventricular assist device in a patient with dextrocardia. Journal of Heart and Lung Transplantation, 2005, 24, 338-339.	0.6	6
119	Cellular and Hemodynamics Responses of Failing Myocardium to Continuous Flow Mechanical Circulatory Support Using the DeBakey-Noon Left Ventricular Assist Device: a Comparative Analysis With Pulsatile-Type Devices. Journal of Heart and Lung Transplantation, 2005, 24, 566-575.	0.6	115
120	Impact of Left Venticular Assist Device (LVAD)-mediated Humoral Sensitization on Post-transplant Outcomes. Journal of Heart and Lung Transplantation, 2005, 24, 2054-2059.	0.6	85
121	Tezosentan in patients with acute heart failure: Design of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Study (VERITAS). American Heart Journal, 2005, 150, 46-53.	2.7	67
122	Biological and Functional Effects of Chronic Mechanical Support Induced by Left Ventricular Assist Devices on Failing Human Myocardium. , 2005, , 311-328.		0
123	Altered Titin Expression, Myocardial Stiffness, and Left Ventricular Function in Patients With Dilated Cardiomyopathy. Circulation, 2004, 110, 155-162.	1.6	436
124	The hemodynamic and neurohormonal effects of low doses of tezosentan (an endothelin A/B receptor) Tj ETQqC	00 <u>9.1</u> gBT	Overlock 10
125	Molecular normalization of dystrophin in the failing left and right ventricle of patients treated with either pulsatile or continuous flow-type ventricular assist devices. Journal of the American College of Cardiology, 2004, 43, 811-817	2.8	91

126 Effects of a novel immune modulation therapy in patients with advanced chronic heart failure. Journal of the American College of Cardiology, 2004, 44, 1181-1186.

#	Article	IF	CITATIONS
127	Attenuation of myocardial inflammation by celacadeâ,,¢ (Immune modulation therapy) in a murine model of myosin-induced myocarditis. Journal of Cardiac Failure, 2004, 10, S49.	1.7	1
128	Evidence of improved right ventricular structure after LVAD support in patients with end-stage cardiomyopathy. Journal of Heart and Lung Transplantation, 2004, 23, 28-35.	0.6	51
129	Aldosterone antagonism and congestive heart failure: a new look at an old therapy. Current Opinion in Cardiology, 2004, 19, 301-308.	1.8	14
130	Editorial overview: Cardiac failure. Current Opinion in Cardiology, 2004, 19, 228.	1.8	0
131	The response of the failing heart to chronic mechanical unloading. Current Opinion in Cardiology, 2004, 19, 270-277.	1.8	1
132	Effects of a novel immune modulation therapy in patients with advanced chronic heart failureResults of a randomized, controlled, phase II trial. Journal of the American College of Cardiology, 2004, 44, 1181-1186.	2.8	42
133	Hemodynamic and clinical effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients hospitalized for acute decompensated heart failure. Journal of the American College of Cardiology, 2003, 42, 140-147.	2.8	113
134	Dobutamine stress echocardiography predicts myocardial improvement in patients supported by left ventricular assist devices (LVADs): hemodynamic and histologic evidence of improvement before LVAD explantation. Journal of Heart and Lung Transplantation, 2003, 22, 137-146.	0.6	112
135	Revascularization and ventricular restoration in patients with ischemic heart failure: the STICH trial. Current Opinion in Cardiology, 2003, 18, 454-457.	1.8	38
136	New Therapeutics for Chronic Heart Failure. Annual Review of Medicine, 2002, 53, 59-74.	12.2	60
137	Release of matrix metalloproteinases following alcohol septal ablation in hypertrophic obstructive cardiomyopathy. Journal of the American College of Cardiology, 2002, 40, 2165-2173.	2.8	23
138	Molecular remodelling of dystrophin in patients with end-stage cardiomyopathies and reversal in patients on assistance-device therapy. Lancet, The, 2002, 359, 936-941.	13.7	175
139	Use of a donor heart that had undergone previous cardiac surgery for ASD closure. Journal of Heart and Lung Transplantation, 2002, 21, 294-295.	0.6	3
140	The Role of Tumor Necrosis Factor Alpha Blockade in the Treatment of Congestive Heart Failure. Congestive Heart Failure, 2002, 8, 275-279.	2.0	25
141	Atherosclerosis and inflammation. Current Atherosclerosis Reports, 2002, 4, 92-98.	4.8	39
142	The role of inflammation in the pathogenesis of heart failure. Current Cardiology Reports, 2002, 4, 200-205.	2.9	15
143	Regression of fibrosis and hypertrophy in failing myocardium following mechanical circulatory support. Journal of Heart and Lung Transplantation, 2001, 20, 457-464.	0.6	187
144	MANAGING HEART FAILURE WITH IMMUNOMODULATORY AGENTS. Cardiology Clinics, 2001, 19, 617-625.	2.2	9

GUILLERMO TORRE-AMIONE

#	Article	IF	CITATIONS
145	New strategies for the management of acute decompensated heart failure. Current Opinion in Cardiology, 2001, 16, 164-173.	1.8	5
146	The renin angiotensin system as a risk factor for coronary artery disease. Current Atherosclerosis Reports, 2001, 3, 117-124.	4.8	40
147	The effect of cytokines on cardiac allograft function: tumor necrosis factor alpha a mediator of chronic injury. Heart Failure Reviews, 2001, 6, 137-141.	3.9	1
148	Results of Targeted Anti–Tumor Necrosis Factor Therapy With Etanercept (ENBREL) in Patients With Advanced Heart Failure. Circulation, 2001, 103, 1044-1047.	1.6	358
149	A Pilot Safety Trial of Prolonged (48 h) Infusion of the Dual Endothelin-Receptor Antagonist Tezosentan in Patients With Advanced Heart Failure. Chest, 2001, 120, 460-466.	0.8	38
150	Decreased Expression of Tumor Necrosis Factor-α and Regression of Hypertrophy After Nonsurgical Septal Reduction Therapy for Patients With Hypertrophic Obstructive Cardiomyopathy. Circulation, 2001, 103, 1844-1850.	1.6	68
151	Controlled Trial of Intravenous Immune Globulin in Recent-Onset Dilated Cardiomyopathy. Circulation, 2001, 103, 2254-2259.	1.6	515
152	Cardiac Hypertrophy After Transplantation Is Associated With Persistent Expression of Tumor Necrosis Factor-1±. Circulation, 2001, 104, 676-681.	1.6	55
153	Hemodynamic Effects of Tezosentan, an Intravenous Dual Endothelin Receptor Antagonist, in Patients With Class III to IV Congestive Heart Failure. Circulation, 2001, 103, 973-980.	1.6	108
154	The Effect of Cytokines on Cardiac Allograft Function: Tumor Necrosis Factor-α: A Mediator of Chronic Injury. Developments in Cardiovascular Medicine, 2001, , 77-81.	0.1	0
155	Endothelin-1: a new target of therapeutic intervention for the treatment of heart failure. Current Opinion in Cardiology, 2000, 15, 136-140.	1.8	17
156	Cardiac transplantation: the final therapeutic option for the treatment of heart failure. Current Opinion in Cardiology, 2000, 15, 178-182.	1.8	19
157	Heart failure, an evolving field: from drugs to novel nonpharmacologic strategies. Current Opinion in Cardiology, 2000, 15, 127.	1.8	0
158	The implications for cardiac recovery of left ventricular assist device support on myocardial collagen content. American Journal of Surgery, 2000, 180, 498-502.	1.8	56
159	Comparative Tolerability of the HMG-CoA Reductase Inhibitors. Drug Safety, 2000, 23, 197-213.	3.2	160
160	Role of Tumour Necrosis Factor-?? in the Progression of Heart Failure. Drugs, 2000, 59, 745-751.	10.9	32
161	Decreased Expression of Tumor Necrosis Factor-α in Failing Human Myocardium After Mechanical Circulatory Support. Circulation, 1999, 100, 1189-1193.	1.6	248
1(0	Turner Negrovia Factor \hat{i}_{1} Cheat 1000 115 1170 1174	0.0	

162 Tumor Necrosis Factor-α. Chest, 1999, 115, 1170-1174.

0.8 61

Guillermo Torre-Amione

#	Article	IF	CITATIONS
163	The syndrome of heart failure: emerging concepts in the understanding of its pathogenesis and treatment. Current Opinion in Cardiology, 1999, 14, 193.	1.8	16
164	An overview of tumor necrosis factor α and the failing human heart. Current Opinion in Cardiology, 1999, 14, 206.	1.8	77
165	Estimation of left and right ventricular filling pressures after heart transplantation by tissue Doppler imaging. American Journal of Cardiology, 1998, 82, 352-357.	1.6	196
166	Differential Expression of Heat Shock Proteins in Normal and Failing Human Hearts. Journal of Molecular and Cellular Cardiology, 1998, 30, 811-818.	1.9	170
167	Pathophysiology and treatment of lipid perturbation after cardiac transplantation. Current Opinion in Cardiology, 1997, 12, 153-160.	1.8	17
168	Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: A report from the studies of left ventricular dysfunction (SOLVD). Journal of the American College of Cardiology, 1996, 27, 1201-1206.	2.8	1,098
169	Evolving Concepts Regarding Selection of Patients for Cardiac Transplantation. Chest, 1996, 109, 223-232.	0.8	14
170	Tumor Necrosis Factor-α and Tumor Necrosis Factor Receptors in the Failing Human Heart. Circulation, 1996, 93, 704-711.	1.6	833
171	Tumor necrosis factor-α and the failing human heart-TNFα and heart failure. Clinical Cardiology, 1995, 18, IV20-IV27.	1.8	53
172	Expression and Functional Significance of Tumor Necrosis Factor Receptors in Human Myocardium. Circulation, 1995, 92, 1487-1493.	1.6	284
173	Powerful immunosuppression mediated by interleukin 2-activated, nonantigen-specific, or H-2-restricted THY-1+ CD8+ cells. Cellular Immunology, 1989, 124, 50-63.	3.0	4
174	Cobra venom factor, an activator of the complement system, enhances the bowel necrosis induced by platelet-activating factor. Immunopharmacology, 1988, 15, 31-37.	2.0	6